- Home
- FINW vs TVRD Comparison
FINW vs TVRD Comparison
Compare FINW & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FINW | TVRD |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 237.1M | 36.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | FINW | TVRD |
|---|---|---|
| Price | $15.86 | $3.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 8.8K | ★ 38.4K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.51 | N/A |
| EPS | ★ 1.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $160.48 | N/A |
| Revenue Next Year | $35.27 | N/A |
| P/E Ratio | $14.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.49 | $3.05 |
| 52 Week High | $22.49 | $43.65 |
Technical Indicators
Market Signals| Indicator | FINW | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 48.98 | 33.33 |
| Support Level | $15.67 | N/A |
| Resistance Level | $16.51 | $4.52 |
| Average True Range (ATR) | 0.41 | 0.27 |
| MACD | 0.08 | -0.05 |
| Stochastic Oscillator | 67.61 | 7.58 |
Price Performance
Historical ComparisonAbout FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.